Lost, and sometimes found, in the emergency room at Christmas – STAT
I encounter two distinct types of non-emergency patient in the emergency department at Christmas. The common denominator? Lonely living environments.
Related Articles
Trump finally finds a populist health care message in Kennedy’s MAHA
Expectations for change are high as Trump’s MAGA and RFK Jr.’s MAHA movements merge.
UnitedHealth mounts full defense of its business in wake of Thompson’s killing
UnitedHealth’s CEO acknowledged discontent with the health care system, but quickly shifted the blame elsewhere.
The companies paying hospitals to hand over patient data to train AI
A new crop of companies is lining up to buy patient data from hospitals and sell it to those wanting to train AI or do…
The U.S. should reform the WHO, not leave it
“By exiting the WHO and pulling funding, the U.S. would lose any leverage to enact those reforms,” writes Ashish K. Jha.
How the FDA’s new nutrition labels could prod the food industry to get healthier
Front-of-package labels have spurred companies in other countries to cut sugars and salt. The FDA wants to follow suit here.
FTC notches modest victory in reining in Welsh Carson’s anesthesia empire
The FTC announced Friday it reached a settlement with Welsh Carson that limits the private equity firm’s involvement in its anesthesia business, which the agency…
DEA unveils telehealth rules for Adderall, buprenorphine, other controlled medications
The DEA’s long-awaited rule would allow providers on a new registry prescribe controlled medications. But there are restrictions.
Jiangsu Hengrui, a preferred China partner for U.S. biotech, hints at more deals
One of the U.S. biotech industry’s preferred partners in China, Jiangsu Hengrui, emphasized its global ambitions and plans for more dealmaking at #JPM25.
Could inhaling xenon gas help treat Alzheimer’s? A new mouse study suggests it might
A new mouse study shows a possible use case for the gas xenon — as a treatment for Alzheimer’s disease.
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Eli Lilly’s CEO says the company is considering offering more Zepbound doses in vials at lower cost.